Cymabay Therapeutics Inc buy tamam
Start price
21.02.19
/
50%
€8.95
Target price
17.12.19
€20.75
Performance (%)
-81.34%
End price
17.12.19
€1.67
Summary
This prediction ended on 17.12.19 with a price of €1.67. Massive losses of -81.34% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | -1.370% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | 0.172% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.801% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.369% | -2.979% | 26.341% | 40.911% |
Comments by tamam for this prediction
In the thread Cymabay Therapeutics Inc diskutieren
CymaBay with Orphan Drug Status
The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) recommends the designation of Orphan Drug status for CymaBay Therapeutics' (CBAY +2.3%) seladelpar for the treatment of primary biliary cholangitis (PBC), a serious liver disease characterized by the progressive destruction of the bile ducts.
Stopped prediction by tamam for Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
Start price
Target price
Perf. (%)
€6.84
20.09.17
20.09.17
€20.75
20.02.19
20.02.19
33.64%
20.02.19
20.02.19
